Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$202.14 USD

202.14
2,303,503

+0.46 (0.23%)

Updated Nov 6, 2024 01:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Is a Beat Likely for AbbVie (ABBV) This Earnings Season?

by Zacks Equity Research

AbbVie's (ABBV) fourth-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics. Investors are likely to focus on any update related to the guidance for 2022.

Gilead (GILD) to Report Q4 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) fourth-quarter 2021 results.

Kinjel Shah headshot

Pharma Stock Roundup: J&J Q4 Earnings, FDA's Rejection of PFE, MRK Pipeline Drugs

by Kinjel Shah

J&J (JNJ) reports mixed fourth-quarter results. FDA issues CRL to Merck (MRK) and Pfizer's (PFE) pipeline candidates. FDA approves AbbVie's (ABBV) Skyrizi for a second indication.

The Zacks Analyst Blog Highlights: AbbVie, Edwards Lifesciences and Johnson Controls International

by Zacks Equity Research

AbbVie, Edwards Lifesciences and Johnson Controls International are included in this analyst blog.

Benjamin Rains headshot

2 Stocks to Buy During Market Turbulence Before Earnings

by Benjamin Rains

Diving into two strong stocks that also pay a dividend that investors might want to consider buying heading into earnings...

Vedika Agarwal headshot

Should Value Investors Pick AbbVie (ABBV) At Present?

by Vedika Agarwal

Is AbbVie (ABBV) a great pick from the value investor's perspective right now? Read on to know more.

Mark Vickery headshot

Top Analyst Reports for AbbVie, Edwards Lifesciences & Johnson Controls

by Mark Vickery

Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc. (ABBV), Edwards Lifesciences Corporation (EW), and Johnson Controls International plc (JCI).

AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

AbbVie (ABBV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Karyopharm's (KPTI) Eltanexor Gets Orphan Drug Tag for MDS

by Zacks Equity Research

The FDA bestows an Orphan Drug status to Karyopharm's (KPTI) investigational candidate, eltanexor, for treating myelodysplastic syndromes.

J&J (JNJ) Q4 Earnings Beat Estimates by a Penny, Sales Miss

by Zacks Equity Research

J&J (JNJ) reports mixed fourth-quarter results. It beats estimates for earnings but misses the same for sales.

    Johnson & Johnson (JNJ) Surpasses Q4 Earnings Estimates

    by Zacks Equity Research

    Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 0.47% and 1.77%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    AbbVie (ABBV) Gains But Lags Market: What You Should Know

    by Zacks Equity Research

    AbbVie (ABBV) closed at $132.16 in the latest trading session, marking a +0.14% move from the prior day.

    AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis

    by Zacks Equity Research

    AbbVie (ABBV) secures approval in the United States for Skyrizi to treat adult patients with active psoriatic arthritis.

    Kinjel Shah headshot

    Pharma Stock Roundup: GSK's Consumer Unit Offer Rejection, FDA Updates for AZN, PFE

    by Kinjel Shah

    Glaxo (GSK) rejects a $68 billion buyout offer for its consumer healthcare unit from Unilever. FDA updates for Pfizer (PFE), AbbVie (ABBV) and AstraZeneca (AZN) grab headlines.

    J&J (JNJ) to Set the Stage for Pharma Sector Q4 Earnings

    by Zacks Equity Research

    J&J's (JNJ) Pharma segment is expected to have performed above the market. It remains to be seen if sales improved in the Medical Devices segment in the fourth quarter.

    Zacks Value Trader Highlights: AbbVie, The Andersons and Ingredion

    by Zacks Equity Research

    AbbVie, The Andersons and Ingredion are highlighted in this Zacks Value Traders article.

    Tracey Ryniec headshot

    3 Value Stocks Breaking out in 2022

    by Tracey Ryniec

    Not all stocks are selling off to start 2022. These cheap, top Zacks Ranked stocks are doing the opposite.

    Zacks Industry Outlook Highlights: Roche, Pfizer, AbbVie and Merck

    by Zacks Equity Research

    Roche, Pfizer, AbbVie and Merck are highlighted in this Industry Outlook article.

    AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

    by Zacks Equity Research

    In the latest trading session, AbbVie (ABBV) closed at $135.87, marking a +1.76% move from the previous day.

    AbbVie's (ABBV) Rinvoq Gets FDA Nod for Atopic Dermatitis

    by Zacks Equity Research

    FDA approves AbbVie's (ABBV) Rinvoq for the treatment of moderate to severe atopic dermatitis in adults and children aged 12 and above. This is the third indication for Rinvoq in the United States.

    Pfizer's (PFE) Cibinqo Gets FDA Nod for Atopic Dermatitis

    by Zacks Equity Research

    After a series of delays, Pfizer's (PFE) oral JAK inhibitor, Cibinqo (abrocitinib), gets approval for treating adults with atopic dermatitis in the United States.

    Kinjel Shah headshot

    4 Large-Cap Drugmaker Stocks to Watch Despite Omicron Woes

    by Kinjel Shah

    Drug/biotech and medical device companies are likely to remain in the spotlight in 2022. Among the large drugmakers Roche (RHHBY), Pfizer (PFE), AbbVie (ABBV), and Merck (MRK) are worth retaining in your portfolio.

    The Zacks Analyst Blog Highlights: Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo

    by Zacks Equity Research

    Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo are highlighted in this analyst blog article.

    Kinjel Shah headshot

    Pharma Stock Roundup: PFE's Research Deal With BEAM & Other Updates

    by Kinjel Shah

    Pfizer (PFE) inks research collaboration with Beam Therapeutics. Merck's (MRK) Keytruda improves survival in adjuvant lung cancer

    Pfizer's (PFE) Prevnar 20 Plus COVID Vaccine Study Succeeds

    by Zacks Equity Research

    Pfizer's (PFE) data from a phase III study showed that its COVID-19 vaccine and pneumococcal conjugate vaccine, Prevnar-20 can be given at the same time.